SYDNEY, Jan. 23, 2015 /PRNewswire/ -- Novogen (ASX: NRT;
NASDAQ: NVGN), an Australian-US drug discovery company focused on
the development of novel therapeutics in the fields of oncology,
degenerative disease and regenerative medicine, announced today
that Graham Kelly, Ph.D., CEO and
Executive Chairman, will present at the Biotech and Money London
investor conference held during the 3rd-4th
of February 2015.
About Biotech and Money London
Biotech and Money London 2015 is a two-day congress providing
the education, strategies and solutions executives need to enable
more effective funding, investment, business planning and
partnering within your business.
It's where life science meets money, investors uncover
innovation and pharma seek partners.
For more information visit the website:
http://biotechandmoney.com/london
About Novogen Limited
Novogen is a public, Australian drug-development company whose
shares trade on both the Australian Securities Exchange ('NRT') and
NASDAQ ('NVGN'). The Novogen group includes US-based, CanTx Inc, a
joint venture company with Yale
University.
Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been designed to kill the full heterogeneity of
cells within a tumor, including the cancer stem cells. The
molecular target is a trans-membrane electron-transfer pump
mechanism oncogene that is common to all cancer cells. Cells die by
respiratory distress and mitochondrial disintegration.
The ATM compounds target the micro-filament component of the
cancer cell's cytoskeleton and have been designed to combine with
anti-microtubular drugs (taxanes, vinca alkaloids) to produce
comprehensive and fatal destruction of the cancer cell
cytoskeleton.
The Company pipeline comprises three SBP drug candidates
(TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate
('Anisina').
Further information is available on our websites
www.novogen.com
For more information please contact:
Corporate
Contact
Dr. Graham
Kelly
Executive Chairman
& CEO Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472
4100
|
Media
Enquiries
Cristyn
Humphreys
Chief Operating
Officer Novogen Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472
4111
|